Bank of America Corp DE Decreases Stock Position in BioNTech SE (NASDAQ:BNTX)

Bank of America Corp DE cut its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 65.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 74,451 shares of the company's stock after selling 139,203 shares during the period. Bank of America Corp DE's holdings in BioNTech were worth $8,484,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Jones Financial Companies Lllp boosted its holdings in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after buying an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. raised its position in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after acquiring an additional 700 shares in the last quarter. Allianz SE acquired a new stake in BioNTech in the fourth quarter valued at $90,000. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in BioNTech in the fourth quarter valued at $137,000. Finally, AlphaCentric Advisors LLC bought a new position in shares of BioNTech in the 4th quarter valued at about $168,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Performance

BNTX traded down $0.13 during midday trading on Tuesday, reaching $98.55. The company had a trading volume of 842,090 shares, compared to its average volume of 919,814. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a market cap of $23.69 billion, a PE ratio of -46.93 and a beta of 1.35. The business has a 50-day moving average price of $97.39 and a two-hundred day moving average price of $108.38. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter last year, the firm posted $1.90 EPS. The firm's revenue for the quarter was down 19.5% on a year-over-year basis. On average, sell-side analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Morgan Stanley decreased their target price on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. BMO Capital Markets increased their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Finally, HC Wainwright restated a "buy" rating and set a $134.00 target price on shares of BioNTech in a research note on Thursday, May 22nd. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $141.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.